Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q2 FY27 consolidated revenue 295cr +23% y-y; EBITDA 92cr; PAT 56cr
- Standalone revenue 226cr +11% q-q; EBITDA margin 36%, PAT margin 24%
- HALS segment revenue doubled y-y; volumes at 30-35% capacity, targeting 55-60%
- New advanced HALS product commercial launch expected H2 FY27; backward integration to improve margins by 5-7%
- Performance Chemical 2 capex ongoing; commissioning expected Q4 FY27
- Raw material costs high due to crude-linked feedstock; pass-through to customers limited
- Volume-led growth in Q2; realization-led growth y-y; maintaining absolute EBITDA despite margin pressure
- Barbituric acid production on hold due to uncompetitive pricing
- Management cautious on margin outlook amid macro and crude price volatility
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 CLEAN — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add CLEAN to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Clean Science and Technology Limited
Important.
The summary above is generated automatically from Clean Science and Technology Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.